When ovarian cancers recur in the first 6 months after standard treatment it is generally accepted that there is a need for exceptional or salvage therapy. Usually the salvage treatment course involves repeat chemotherapy, with PARP inhibitors being added or recommenced.
It is becoming clear that this approach to platinum resistant ovarian cancer is simplistic and that these patients have special needs and are liable to significant adverse effects from therapy, meaning platinum chemo and enzyme inhibition may be harmful.
This study looks at 182 women who commenced salvage therapy and recorded the high risk of hematological disorders. 16 of the women developed marrow cancers, 4 died very soon after diagnosis with only 3 surviving six months later. 10 dying from Leukaemia and 2 from transplant reaction. The authors suggest that management of salvage therapy is complex and the outcomes are poor.
No comments:
Post a Comment